scholarly journals Pure Large Cell Neuroendocrine Carcinoma of Ovary: A Rare Clinical Entity and Review of Literature

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
P. N. Shakuntala ◽  
K. Uma Devi ◽  
K. Shobha ◽  
U. D. Bafna ◽  
M. Geetashree
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Neuroendocrine Tumour ◽  
Early Stage ◽  
Intraepithelial Neoplasia ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
World Health ◽  
Type I ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
Large Tumor

Large cell neuroendocrine carcinoma (LCNEC) of the ovary is a rare tumor and is now included in the World Health Organization tumor classification. Its prognosis is generally very poor even when the diagnosis is made at an early stage. We report a case of pure large cell neuroendocrine tumour of ovary, appearing 9 months following laparoscopic type I hysterectomy, bilateral pelvic lymph node dissection with ovarian preservation of anatomically normal looking ovaries performed for a cervical biopsy diagnosis of cervical intraepithelial neoplasia grade III with foci of invasion. The rarity lies in the rapid onset (9 months) of a large tumor following conservation of an anatomically normal ovaries. Surgical debulking and five cycles of chemotherapy (Etoposide and Cisplatin) were administered to the woman. She is on followup with no clinical or radiological evidence of disease recurrence for 6 months.

scholarly journals Clinical features of large cell neuroendocrine carcinoma: a population-based overview

2015 ◽  
Vol 47 (2) ◽  
pp. 615-624 ◽  
Author(s):  
Jules L. Derks ◽  
Lizza E. Hendriks ◽  
Wieneke A. Buikhuisen ◽  
Harry J.M. Groen ◽  
Erik Thunnissen ◽  
...  
Keyword(s):  
The Netherlands ◽  
Cancer Registry ◽  
Neuroendocrine Carcinoma ◽  
Early Stage ◽  
Small Cell Lung Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Stage I ◽  
Cell Lung Carcinoma ◽  
Netherlands Cancer Registry

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an orphan disease and few data are available on its clinical characteristics. Therefore, we analysed LCNEC registered in the Netherlands Cancer Registry, and compared data with small cell lung carcinoma (SCLC), squamous cell carcinoma (SqCC) and adenocarcinoma (AdC).Histologically confirmed LCNEC (n=952), SCLC (n=11 844), SqCC (n=19 633) and AdC (n=24 253) cases were selected from the Netherlands Cancer Registry (2003–2012). Patient characteristics, metastasis at diagnosis (2006 or later), overall survival (OS) including multivariate Cox models and first-line treatment were compared for stage I–II, III and IV disease.The number of LCNEC cases increased from 56 patients in 2003 to 143 in 2012, accounting for 0.9% of all lung cancers. Stage IV LCNEC patients (n=383) commonly had metastasis in the liver (47%), bone (32%) and brain (23%), resembling SCLC. Median OS (95% CI) of stage I–II, III and IV LCNEC patients was 32.4 (22.0–42.9), 12.6 (10.3–15.0) and 4.0 (3.5–4.6) months, respectively. Multivariate-adjusted OS of LCNEC patients resembled that of SCLC patients, and was poorer than those of SqCC and AdC patients. However, frequency of surgical resection and adjuvant chemotherapy resembled SqCC and AdC more than SCLC.Diagnosis of LCNEC has increased in recent years. The metastatic pattern of LCNEC resembles SCLC as does the OS. However, early-stage treatment strategies seem more comparable to those of SqCC and AdC.

scholarly journals Survival After Lobectomy Versus Sublobar Resection for Stage IA Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

2021 ◽  
Author(s):  
xiangyang yu ◽  
Zirui Huang ◽  
Mengqi Zhang ◽  
Yongbin Lin ◽  
Rusi Zhang ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Lymph Nodes ◽  
Neuroendocrine Carcinoma ◽  
Early Stage ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Sublobar Resection ◽  
Oncological Outcomes ◽  
Stage Ia ◽  
Lymph Nodes Dissection

Abstract Background: Due to the low incidence of pulmonary large cell neuroendocrine carcinoma (LCNEC), the survival analysis for comparing lobectomy and sublobar resection (SLR) for stage IA LCNEC remains scarce. Methods: Patients diagnosed with pathological stage IA LCNEC between 1998 and 2016 were extracted from the Survenillance, Epidemiology, and End Results (SEER) database. The oncological outcomes were cancer-specific survival (CSS) and overall survival (OS). Kaplan-Meier analysis and Cox multivariate analysis were used to identify the independent prognostic factors for OS and CSS. Furthermore, propensity score matching (PSM) was performed between SLR and lobectomy to adjust the confounding factors. Results: A total of 308 patients with stage IA LCNEC met the inclusion criteria: 229 patients (74.4%) received lobectomy and 79 patients (25.6%) received SLR. Patients who underwent SLR were older (P<0.001), had smaller tumor size (P=0.010) and fewer lymph nodes dissection (P<0.001). The 5-year CSS and OS rates were 56.5% and 42.9% for SLR, and 67.8% and 55.7% for lobectomy, respectively (P=0.037 and 0.019, respectively). However, multivariate analysis did not identify any differences between SLR group and lobectomy group in CSS (P=0.135) and OS (P=0.285); and the PSM also supported these results. In addition, age at diagnosis and laterality of tumor were identified as significant predictors for CSS and OS, whereas the number of lymph nodes dissection was a significant predictor for CSS. Conclusions: Although SLR is not inferior to lobectomy in terms of oncological outcomes for patients with stage IA LCNEC, more lymph nodes can be dissected or sampled during lobectomy. Lobectomy should be considered as a standard procedure for patients with early-stage LCNEC who are able to withstand lobectomy.

Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma

Cancer ◽  
2004 ◽  
Vol 100 (6) ◽  
pp. 1190-1198 ◽  
Author(s):  
Kenzo Hiroshima ◽  
Akira Iyoda ◽  
Kiyoshi Shibuya ◽  
Yukiko Haga ◽  
Tetsuya Toyozaki ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Early Stage ◽  
Large Cell ◽  
Genetic Alterations ◽  
Large Cell Neuroendocrine Carcinoma

scholarly journals Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments

2021 ◽  
Vol 11 ◽  
Author(s):  
Masayo Yoshimura ◽  
Kurumi Seki ◽  
Andrey Bychkov ◽  
Junya Fukuoka
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Molecular Subtypes ◽  
Small Cell Lung Carcinoma ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
Type I ◽  
Histologic Diagnosis ◽  
Cell Lung Carcinoma ◽  
Genomic Studies ◽  
Poorly Differentiated

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive neoplasm with poor prognosis. Histologic diagnosis of LCNEC is not always straightforward. In particular, it is challenging to distinguish small cell lung carcinoma (SCLC) or poorly differentiated carcinoma from LCNEC. However, histological classification for LCNEC as well as their therapeutic management has not changed much for decades. Recently, genomic and transcriptomic analyses have revealed different molecular subtypes raising hopes for more personalized treatment. Two main molecular subtypes of LCNEC have been identified by studies using next generation sequencing, namely type I with TP53 and STK11/KEAP1 alterations, alternatively called as non-SCLC type, and type II with TP53 and RB1 alterations, alternatively called as SCLC type. However, there is still no easy way to classify LCNEC subtypes at the actual clinical level. In this review, we have discussed histological diagnosis along with the genomic studies and molecular-based treatment for LCNEC.

scholarly journals A rare presentation of an ACTH-producing high grade large cell neuroendocrine carcinoma with Cushing's syndrome

2021 ◽  
Author(s):  
Francis Essien ◽  
Christine Persaud ◽  
David Dado ◽  
Joshua Tate ◽  
George Shahin
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Rare Case ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma ◽  
World Health ◽  
High Grade ◽  
Rare Tumor ◽  
Rare Presentation ◽  
The World ◽  
Health Organization

Large cell neuroendocrine carcinoma (LCNEC) was first proposed by Travis et al. in 1991 and subsequently classified as high grade neuroendocrine carcinoma (HGNEC) by the world health organization. It is a rare tumor with unclear clinicopathologic features. Herein, we describe a rare case of LCNEC with a unique Cushing’s presentation.

Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma

2020 ◽  
Vol 159 (5) ◽  
pp. 2043-2054.e9 ◽  
Author(s):  
Elliot Wakeam ◽  
Alex Adibfar ◽  
Sean Stokes ◽  
Natasha B. Leighl ◽  
Meredith E. Giuliani ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Neuroendocrine Carcinoma ◽  
Early Stage ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma

scholarly journals Role of diagnostic laparoscopy in patients with large cell neuroendocrine carcinoma of the ovary with cancerous peritonitis: case report and review of the literature

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Hideaki Tsuyoshi ◽  
Kenji Yashiro ◽  
Shizuka Yamada ◽  
Makoto Yamamoto ◽  
Toshimichi Onuma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Neuroendocrine Carcinoma ◽  
Cytoreductive Surgery ◽  
Diagnostic Laparoscopy ◽  
Early Stage ◽  
Advanced Ovarian Cancer ◽  
Large Cell ◽  
Large Cell Neuroendocrine Carcinoma

Abstract Background Large cell neuroendocrine carcinoma is a very rare ovarian neoplasm that has a poor clinical outcome even in the early stage, and there is as yet no established treatment. Diagnostic laparoscopy has been used to determine the possibility of primary optimal cytoreductive surgery or neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. However, the role of diagnostic laparoscopy is still unclear in large cell neuroendocrine carcinoma due to its rarity. Case presentation A 31-year-old woman with abdominal distention was referred to our hospital. She was strongly suspected of having advanced ovarian cancer because of a huge pelvic mass, massive ascites, and their appearance on medical imaging. However, cytological examinations from ascitic fluid by abdominal paracentesis did not show any malignant cells. She underwent diagnostic laparoscopy to evaluate the possibility of primary optimal cytoreductive surgery, and only tissue sampling was performed for pathological diagnosis because of the countless disseminated lesions of various sizes in the intraperitoneal organs. The patient had no postoperative complications, leading to the early start of postoperative chemotherapy. Conclusions To date, there have been no systematic reviews that focused on determining the treatment strategy using laparoscopy. Diagnostic laparoscopy can be helpful to determine the optimal treatment, including primary debulking surgery, neoadjuvant chemotherapy, or best supportive care, assisting in decision-making particularly for patients with advanced large cell neuroendocrine carcinoma with carcinomatous peritonitis.

Sign in / Sign up

Export Citation Format

Share Document